<p>Precision BioSciences, Inc.（纳斯达克代码：DTIL - 获取免费报告）董事 Geno Germano 于 12 月 16 日（星期二）购买了 3,000 股 Precision BioSciences 的股票。该股票的平均购买成本为每股 4.72 美元，总价值为 14,160.00 美元。购买后，该董事在公司持有 23,883 股，价值 112,727.76 美元。此次交易使其持股增加了 14.37%。该交易已在向美国证券交易委员会（SEC）的备案中披露，相关信息可通过 SEC 网站获取。</p>
<p>获取 <strong>Precision BioSciences</strong> 的提醒：</p>
<h2>Precision BioSciences 股票表现</h2>
<p>在周三的午盘交易中，DTIL 上涨 0.11 美元，达到 4.93 美元。该公司的股票交易量为 16,762 股，而其平均交易量为 270,651 股。该公司的流动比率为 3.45，速动比率为 3.45，债务与股本比率为 1.35。该股票的市值为 6537 万美元，市盈率为-0.59，贝塔值为 1.11。该公司 50 日简单移动平均线为 5.94 美元，200 日简单移动平均线为 5.22 美元。Precision BioSciences, Inc.的 12 个月最低价为 3.61 美元，最高价为 8.82 美元。</p>
<p>Precision BioSciences（纳斯达克代码：DTIL - 获取免费报告）最近于 11 月 3 日（星期一）公布了季度财报。该公司报告本季度每股收益（EPS）为-1.84 美元，低于市场共识预期的-0.31 美元，差距为-1.53 美元。该公司在本季度的收入为 0.01 百万美元，而市场共识预期为 540 万美元。Precision BioSciences 的净利润率为-11,977.36%，股本回报率为-233.77%。去年同期，该公司每股收益为-2.25 美元。研究分析师预计 Precision BioSciences, Inc.在当前年度的每股收益将为-1.23 美元。</p>
<h2>分析师评级上调与下调</h2>
<p>另外，Weiss Ratings 在周一的研究报告中重申了对 Precision BioSciences 股票的 “卖出（e+）” 评级。两位研究分析师给予该股票买入评级，一位给予卖出评级。根据 MarketBeat 的数据，Precision BioSciences 的共识评级为 “持有”，共识目标价为 47.00 美元。</p>
<p><strong>查看我们最新的 Precision BioSciences 股票报告</strong></p>
<h2>Precision BioSciences 的机构交易</h2>
<p>对冲基金最近调整了对该股票的持有。Geode Capital Management LLC 在第二季度将其在 Precision BioSciences 的持仓增加了 5.5%。Geode Capital Management LLC 目前持有 77,712 股该公司股票，价值 326,000 美元，此前在上个季度购买了 4,025 股。Bridgeway Capital Management LLC 在第二季度获得了 Precision BioSciences 的新股份，价值约 260,000 美元。Corient Private Wealth LLC 在第二季度购买了 Precision BioSciences 的新股份，价值约 425,000 美元。Vanguard Personalized Indexing Management LLC 在第三季度购买了 Precision BioSciences 的新股份，价值 72,000 美元。最后，Vanguard Group Inc.在第三季度将其在 Precision BioSciences 的持仓增加了 21.5%。Vanguard Group Inc.目前持有 492,596 股该公司股票，价值 2,719,000 美元，此前在上个季度购买了 87,242 股。机构投资者和对冲基金持有该公司 37.99% 的股票。</p>
<h2>Precision BioSciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Precision BioSciences, Inc.是一家先进的基因编辑公司，开发用于基因编辑的体内基因编辑疗法，包括基因消除、插入和切除。该公司提供 ARCUS 基因组编辑平台，用于 DNA 基因的插入、删除和修复。它还提供 PBGENE-HBV，用于治疗慢性乙型肝炎病毒（HBV），以消除共价闭合环状 DNA，并直接切割和编辑，以及使整合的 HBV DNA 失活，旨在长期减少乙型肝炎表面抗原；PBGENE-PMM 用于治疗与 m.3243 相关的原发性线粒体肌病（PMM），预计将提交 IND 和/或 CTA。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Precision BioSciences</li>
<li>如何知道购买哪种加密货币：投资者指南</li>
<li>工业领域的大规模突破：现在必须关注的三只股票</li>
<li>如何一步一步购买便宜股票</li>
<li>三只科技股下跌超过 60%——哪一只值得购买？</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复过来</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Precision BioSciences 吗？</h2>
<p>在考虑 Precision BioSciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Precision BioSciences 并不在名单上。</p>
<p>虽然 Precision BioSciences 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

DTIL

<p>Precision BioSciences 的董事 Geno Germano 以每股 4.72 美元的价格购买了 3,000 股，总计 14,160 美元，增加了 14.37% 的持股比例。该交易已向美国证券交易委员会（SEC）披露。该公司的股票表现显示最近的交易价格为 4.93 美元，市值为 6,537 万美元。分析师对该股票的评级不一，普遍维持 “持有” 评级，目标价格为 47.00 美元。机构投资者持有该股票的 37.99%</p>

<p>Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) Director Geno Germano acquired 3,000 shares of Precision BioSciences stock in a transaction that occurred on Tuesday, December 16th. The stock was acquired at an average cost of $4.72 per share, with a total value of $14,160.00. Following the purchase, the director owned 23,883 shares in the company, valued at $112,727.76. The trade was a 14.37% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Precision BioSciences, Inc.（纳斯达克代码：DTIL - 获取免费报告）董事 Geno Germano 于 12 月 16 日（星期二）购买了 3,000 股 Precision BioSciences 的股票。该股票的平均购买成本为每股 4.72 美元，总价值为 14,160.00 美元。购买后，该董事在公司持有 23,883 股，价值 112,727.76 美元。此次交易使其持股增加了 14.37%。该交易已在向美国证券交易委员会（SEC）的备案中披露，相关信息可通过 SEC 网站获取。</p>
</div><p>Get <strong>Precision BioSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Precision BioSciences</strong> 的提醒：</p>
</div><h2>Precision BioSciences Stock Performance</h2>
<div class="lb-trans"><h2>Precision BioSciences 股票表现</h2>
</div><p>DTIL traded up $0.11 during midday trading on Wednesday, reaching $4.93. The company's stock had a trading volume of 16,762 shares, compared to its average volume of 270,651. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The stock has a market cap of $65.37 million, a P/E ratio of -0.59 and a beta of 1.11. The company has a fifty day simple moving average of $5.94 and a 200 day simple moving average of $5.22. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $8.82.</p>
<div class="lb-trans"><p>在周三的午盘交易中，DTIL 上涨 0.11 美元，达到 4.93 美元。该公司的股票交易量为 16,762 股，而其平均交易量为 270,651 股。该公司的流动比率为 3.45，速动比率为 3.45，债务与股本比率为 1.35。该股票的市值为 6537 万美元，市盈率为-0.59，贝塔值为 1.11。该公司 50 日简单移动平均线为 5.94 美元，200 日简单移动平均线为 5.22 美元。Precision BioSciences, Inc.的 12 个月最低价为 3.61 美元，最高价为 8.82 美元。</p>
</div><p>Precision BioSciences (NASDAQ:DTIL - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same period last year, the firm earned ($2.25) EPS. Research analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current year.</p>
<div class="lb-trans"><p>Precision BioSciences（纳斯达克代码：DTIL - 获取免费报告）最近于 11 月 3 日（星期一）公布了季度财报。该公司报告本季度每股收益（EPS）为-1.84 美元，低于市场共识预期的-0.31 美元，差距为-1.53 美元。该公司在本季度的收入为 0.01 百万美元，而市场共识预期为 540 万美元。Precision BioSciences 的净利润率为-11,977.36%，股本回报率为-233.77%。去年同期，该公司每股收益为-2.25 美元。研究分析师预计 Precision BioSciences, Inc.在当前年度的每股收益将为-1.23 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Precision BioSciences in a research note on Monday. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Precision BioSciences has a consensus rating of &#34;Hold&#34; and a consensus price target of $47.00.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在周一的研究报告中重申了对 Precision BioSciences 股票的 “卖出（e+）” 评级。两位研究分析师给予该股票买入评级，一位给予卖出评级。根据 MarketBeat 的数据，Precision BioSciences 的共识评级为 “持有”，共识目标价为 47.00 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Precision BioSciences</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Precision BioSciences 股票报告</strong></p>
</div><h2>Institutional Trading of Precision BioSciences</h2>
<div class="lb-trans"><h2>Precision BioSciences 的机构交易</h2>
</div><p>Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company's stock valued at $326,000 after purchasing an additional 4,025 shares in the last quarter. Bridgeway Capital Management LLC acquired a new stake in Precision BioSciences during the second quarter worth approximately $260,000. Corient Private Wealth LLC bought a new position in shares of Precision BioSciences during the 2nd quarter worth approximately $425,000. Vanguard Personalized Indexing Management LLC bought a new position in Precision BioSciences during the third quarter worth $72,000. Finally, Vanguard Group Inc. increased its position in Precision BioSciences by 21.5% in the 3rd quarter. Vanguard Group Inc. now owns 492,596 shares of the company's stock valued at $2,719,000 after buying an additional 87,242 shares in the last quarter. Institutional investors and hedge funds own 37.99% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近调整了对该股票的持有。Geode Capital Management LLC 在第二季度将其在 Precision BioSciences 的持仓增加了 5.5%。Geode Capital Management LLC 目前持有 77,712 股该公司股票，价值 326,000 美元，此前在上个季度购买了 4,025 股。Bridgeway Capital Management LLC 在第二季度获得了 Precision BioSciences 的新股份，价值约 260,000 美元。Corient Private Wealth LLC 在第二季度购买了 Precision BioSciences 的新股份，价值约 425,000 美元。Vanguard Personalized Indexing Management LLC 在第三季度购买了 Precision BioSciences 的新股份，价值 72,000 美元。最后，Vanguard Group Inc.在第三季度将其在 Precision BioSciences 的持仓增加了 21.5%。Vanguard Group Inc.目前持有 492,596 股该公司股票，价值 2,719,000 美元，此前在上个季度购买了 87,242 股。机构投资者和对冲基金持有该公司 37.99% 的股票。</p>
</div><h2>Precision BioSciences Company Profile</h2>
<div class="lb-trans"><h2>Precision BioSciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.</p>
<div class="lb-trans"><p>Precision BioSciences, Inc.是一家先进的基因编辑公司，开发用于基因编辑的体内基因编辑疗法，包括基因消除、插入和切除。该公司提供 ARCUS 基因组编辑平台，用于 DNA 基因的插入、删除和修复。它还提供 PBGENE-HBV，用于治疗慢性乙型肝炎病毒（HBV），以消除共价闭合环状 DNA，并直接切割和编辑，以及使整合的 HBV DNA 失活，旨在长期减少乙型肝炎表面抗原；PBGENE-PMM 用于治疗与 m.3243 相关的原发性线粒体肌病（PMM），预计将提交 IND 和/或 CTA。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Precision BioSciences</li>
<li>How to Know Which Cryptocurrency to Buy: A Guide for Investors</li>
<li>Massive Breakout in Industrials: 3 Must-Watch Stocks Now</li>
<li>How to Buy Cheap Stocks Step by Step</li>
<li>3 Tech Stocks Down Over 60%—Which One Is Worth Buying?</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>25 Years Later, Cisco Finally Recovers From the Dot-Com Crash</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Precision BioSciences</li>
<li>如何知道购买哪种加密货币：投资者指南</li>
<li>工业领域的大规模突破：现在必须关注的三只股票</li>
<li>如何一步一步购买便宜股票</li>
<li>三只科技股下跌超过 60%——哪一只值得购买？</li>
<li>为什么特别股息对收入投资者来说可能是一个令人愉快的惊喜</li>
<li>25 年后，思科终于从互联网泡沫崩溃中恢复过来</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFRJTA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=DTIL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Precision BioSciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Precision BioSciences 吗？</h2>
</div><p>Before you consider Precision BioSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Precision BioSciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Precision BioSciences 并不在名单上。</p>
</div><p>While Precision BioSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Precision BioSciences 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Precision BioSciences（纳斯达克代码：DTIL）的董事 Geno Germano 购买了 3,000 股股票